Matthew Sykes
Stock Analyst at Goldman Sachs
(3.26)
# 501
Out of 5,182 analysts
197
Total ratings
54.01%
Success rate
11.26%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $15.43 | -67.60% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.61 | -34.92% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $21.60 | -69.91% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $44.16 | +1.90% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.29 | +86.48% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $56.85 | -15.57% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $15.78 | +7.73% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $124.49 | +28.52% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $8.96 | +11.61% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $101.00 | +23.76% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $8.31 | +68.47% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $171.16 | +40.22% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $21.85 | +18.99% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $177.62 | -4.29% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $95.70 | -41.48% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $40.77 | +96.22% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.41 | +6.38% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $194.24 | -2.18% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $2.68 | -34.70% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $4.85 | -12.37% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $40.42 | -8.46% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $178.71 | +39.89% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $2.83 | +749.56% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,124.46 | +15.61% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.93 | +34.38% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $465.00 | +37.63% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $115.62 | +25.41% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $33.04 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $15.43
Upside: -67.60%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.61
Upside: -34.92%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $21.60
Upside: -69.91%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $44.16
Upside: +1.90%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.29
Upside: +86.48%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $56.85
Upside: -15.57%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $15.78
Upside: +7.73%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $124.49
Upside: +28.52%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $8.96
Upside: +11.61%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $101.00
Upside: +23.76%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $8.31
Upside: +68.47%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $171.16
Upside: +40.22%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $21.85
Upside: +18.99%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $177.62
Upside: -4.29%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $95.70
Upside: -41.48%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $40.77
Upside: +96.22%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.41
Upside: +6.38%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $194.24
Upside: -2.18%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $2.68
Upside: -34.70%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $4.85
Upside: -12.37%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $40.42
Upside: -8.46%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $178.71
Upside: +39.89%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $2.83
Upside: +749.56%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,124.46
Upside: +15.61%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.93
Upside: +34.38%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $465.00
Upside: +37.63%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $115.62
Upside: +25.41%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $33.04
Upside: -